The present solution relates to a stable particulate pharmaceutical composition, comprising solifenacin or a salt thereof and a binder having an action of stabilizing solifenacin or a salt thereof, whereby the binder is one or more substances having a glass transition point or melting point lower than 174 øC selected from the group consisting of polyethylene glycol, polyethylene oxide, a polyoxyethylene /polyoxypropylene block copolymer, hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, methacrylic acid copolymer, aminoalkyl methacrylate copolymer, maltose and polyvinyl alcohol. The stable particulate pharmaceutical composition of solifenacin or a salt thereof has spherical form suitable for coating and its degradation can be inhibited during the time when the pharmaceutical composition of solifenacin or a salt supplied for clinical use. Further, there is provided a granular composition of solifenacin or its salt further stabilized by addition of crystallization promoting treatment after production of the granular pharmaceutical composition.The present solution relates to a stable particulate pharmaceutical composition, comprising solifenacin or a salt thereof and a binder having an action of stabilizing solifenacin or a salt thereof, whereby the binder is one or more substances having a glass transition point or melting point lower than 174 řC selected from the group consisting of polyethylene glycol, polyethylene oxide, a polyoxyethylene /polyoxypropylene block copolymer, hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, methacrylic acid copolymer, aminoalkyl methacrylate copolymer, maltose and polyvinyl alcohol. The stable particulate pharmaceutical composition of solifenacin or a salt thereof has spherical form suitable for coating and its degradation can be inhibited during the time when the pharmaceutical composition of solifenacin or a salt supplied for clinical use. Further, there is provided a granular composition of solifena
